Clinical practice guidelines

The Society for Endocrinology’s Clinical Committee has taken the lead on, or contributed to, the development of a number of clinical practice guidelines/guidance for rare endocrine conditions where the availability of guidance will benefit patient care. Guidelines/guidance that have been completed or are currently in process are listed below:

  • Disorders of sex development (2011) Professor S Faisal Ahmed (Society for Endocrinology and British Society of Paediatric Endocrinology & Diabetes) chaired a writing group to develop guidelines for the initial approach to an infant or an adolescent with a suspected disorder of sex development. Click here to view document (pdf) (338kb)
  • Pituitary apoplexy (2011) Professor John Wass (Society for Endocrinology and Royal College of Physicians) chaired a working group to develop UK Guidelines for the Management of Pituitary Apoplexy. Click here to view document (pdf) (504kb).
  • Androgens, health and sexuality in women and men (2010) Professor Kevan Wylie (British Society for Sexual Medicine) led a writing group, including Professor Fredrick Wu (Society for Endocrinology Andrology SIG convenor), to develop guidelines for the management of testosterone deficiency in both women and men. Click here to view document (pdf) (142kb)
  • Multiple Endocrine Neoplasia (in preparation) Professor Raj Thakker (Society for Endocrinology) is chairing a working group to develop guidelines for management of hereditary endocrine cancer syndromes.
  • Congenital adrenal hyperplasia in the adult (in preparation) led by Prof Wiebke Arlt (Society for Endocrinology).
  • Late effects  of cancer therapy (in preparation) led by Professor John Wass and Dr Andy Toogood.
  • Turner’s syndrome (in preparation) led by Dr Gerry Conway (Society for Endocrinology)
  • Vitamin D (in preparation) Dr Peter Selby (Society for Endocrinology Clinical Committee member) and Dr Neil Gittoes (Society for Endocrinology Bone and Mineral SIG convenor) are representing the Society for Endocrinology on a National Osteoporosis Society working group developing guidelines on Vitamin D.

Further Guidance

In addition to the development of guidelines, the Society for Endocrinology’s Clinical Committee has itself or in collaboration with other bodies produced information that endocrinologists might find useful in their clinical practice. Guidance on the subjects listed below can be found on the Society’s Practice and Policy pages:

  • Position statement on the use of dopamine agonists in endocrine disorders (November 2011)
    This statement, originally issued in February 2009 in response to information contained in the MHRA Drug Safety Update (Volume 2, Issue 3 October 2008), has been reviewed and found to remain relevant.
  • Use of synthetic ACTH (Synacthen) in patients with a history of asthma (September2011)
    This statement, authored by Professor Ashley Grossman (Oxford) on behalf of the Society for Endocrinology, is issued to coincide with the publication of BNF62 that contains (in section 6.5.1) an amendment to cautions and contraindications in the use of Tetracosactide (Tetracosactrin).
  • Endocrine effects of inhaled steroids in respiratory disease (July 2011)
    This position statement, authored by Professor Ashley Grossman (Oxford) and Dr Jeremy Tomlinson (Birmingham) on behalf of the Society for Endocrinology, highlights the suppressive effects of inhaled corticosteroids on the endogenous hypothalamo-pituitary-adrenal axis.
  • Protocol used to prepare patients with catecholamine-secreting phaeochromocytoma and paraganglioma for surgery using oral phenoxybenzamine (August 2010)
    Supplies of licensed phenoxybenzamine injection are currently unavailable and there is little indication of when supplies will be restored. It has become apparent that some endocrinologists do not use intravenous phenoxybenzamine pre-operatively but rather use high doses of the oral preparation; such a protocol may provide an alternative means of preparing patients for surgery whilst supplies of the intravenous compound are being restored. One such protocol, adapted from that used by Mr Barney Harrison and Dr John Newell-Price (Sheffield) has been  approved by the Society for Endocrinology.